BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28324044)

  • 1. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
    Audet-Walsh É; Yee T; Tam IS; Giguère V
    Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of 5α-Reduced Androgens in Humans and Eels: 5α-Dihydrotestosterone and 11-Ketodihydrotestosterone Are Active Androgens Produced in Eel Gonads.
    Yazawa T; Inaba H; Imamichi Y; Sekiguchi T; Uwada J; Islam MS; Orisaka M; Mikami D; Ida T; Sato T; Miyashiro Y; Takahashi S; Khan MRI; Suzuki N; Umezawa A; Kitano T
    Front Endocrinol (Lausanne); 2021; 12():657360. PubMed ID: 33833737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN; Rivest P; Sanderson JT
    Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.
    Li J; Ding Z; Wang Z; Lu JF; Maity SN; Navone NM; Logothetis CJ; Mills GB; Kim J
    PLoS One; 2011; 6(12):e28840. PubMed ID: 22194926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice.
    Windahl SH; Andersson N; Börjesson AE; Swanson C; Svensson J; Movérare-Skrtic S; Sjögren K; Shao R; Lagerquist MK; Ohlsson C
    PLoS One; 2011; 6(6):e21402. PubMed ID: 21731732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5α-reduction of epitestosterone is catalysed by human SRD5A1 and SRD5A2 and increases androgen receptor transactivation.
    Schiffer L; Arlt W; Storbeck KH
    J Steroid Biochem Mol Biol; 2024 Jul; 241():106516. PubMed ID: 38582131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
    Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
    Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
    Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonal expression of 5α-reductases and androgen receptor in the prostate gland of the wild ground squirrel (Spermophilus dauricus).
    Zhang Y; Wang Y; Huang C; Wang Y; Qi H; Han Y; Yuan Z; Weng Q; Zhang H
    Comp Biochem Physiol A Mol Integr Physiol; 2018 Dec; 226():11-16. PubMed ID: 30057358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.
    Chang KH; Li R; Papari-Zareei M; Watumull L; Zhao YD; Auchus RJ; Sharifi N
    Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13728-33. PubMed ID: 21795608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
    Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
    Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
    Seok J; Kwak HJ; Kwak Y; Lee M; Park KS; Kim A; Cho SG
    J Transl Med; 2023 Feb; 21(1):129. PubMed ID: 36800968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
    Wako K; Kawasaki T; Yamana K; Suzuki K; Jiang S; Umezu H; Nishiyama T; Takahashi K; Hamakubo T; Kodama T; Naito M
    J Clin Pathol; 2008 Apr; 61(4):448-54. PubMed ID: 17720776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
    Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
    J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.